MX2024000748A - Terapia génica de kcnv2. - Google Patents
Terapia génica de kcnv2.Info
- Publication number
- MX2024000748A MX2024000748A MX2024000748A MX2024000748A MX2024000748A MX 2024000748 A MX2024000748 A MX 2024000748A MX 2024000748 A MX2024000748 A MX 2024000748A MX 2024000748 A MX2024000748 A MX 2024000748A MX 2024000748 A MX2024000748 A MX 2024000748A
- Authority
- MX
- Mexico
- Prior art keywords
- kcnv2
- gene therapy
- vectors
- disclosed
- subject
- Prior art date
Links
- 101100019762 Mus musculus Kcnv2 gene Proteins 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 4
- 101000943985 Homo sapiens Potassium voltage-gated channel subfamily V member 2 Proteins 0.000 abstract 2
- 102100033492 Potassium voltage-gated channel subfamily V member 2 Human genes 0.000 abstract 2
- 208000017442 Retinal disease Diseases 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221879P | 2021-07-14 | 2021-07-14 | |
| PCT/IB2022/056457 WO2023285986A1 (en) | 2021-07-14 | 2022-07-13 | Kcnv2 gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000748A true MX2024000748A (es) | 2024-03-15 |
Family
ID=82932641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000748A MX2024000748A (es) | 2021-07-14 | 2022-07-13 | Terapia génica de kcnv2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240307559A1 (https=) |
| EP (1) | EP4370538A1 (https=) |
| JP (1) | JP2024525742A (https=) |
| KR (1) | KR20240052746A (https=) |
| CN (1) | CN118019757A (https=) |
| AU (1) | AU2022311329A1 (https=) |
| CA (1) | CA3225080A1 (https=) |
| IL (1) | IL310018A (https=) |
| MX (1) | MX2024000748A (https=) |
| WO (1) | WO2023285986A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4345297A1 (de) | 1993-11-11 | 1995-09-28 | Nsm Ag | Geldspielgerät |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| CA2346262A1 (en) | 1998-09-17 | 2000-03-23 | University Of Florida | Methods for treatment of degenerative retinal diseases |
| MA44546B1 (fr) | 2016-06-15 | 2021-03-31 | Univ California | Virus adéno-associés variants et procédés d'utilisation |
| SG11202000840YA (en) * | 2017-07-31 | 2020-02-27 | Reflection Biotechnologies Ltd | Cellular models of and therapies for ocular diseases |
-
2022
- 2022-07-13 WO PCT/IB2022/056457 patent/WO2023285986A1/en not_active Ceased
- 2022-07-13 CN CN202280061604.XA patent/CN118019757A/zh active Pending
- 2022-07-13 US US18/578,623 patent/US20240307559A1/en active Pending
- 2022-07-13 EP EP22754917.7A patent/EP4370538A1/en active Pending
- 2022-07-13 MX MX2024000748A patent/MX2024000748A/es unknown
- 2022-07-13 AU AU2022311329A patent/AU2022311329A1/en active Pending
- 2022-07-13 KR KR1020247004694A patent/KR20240052746A/ko active Pending
- 2022-07-13 JP JP2024501820A patent/JP2024525742A/ja active Pending
- 2022-07-13 CA CA3225080A patent/CA3225080A1/en active Pending
- 2022-07-13 IL IL310018A patent/IL310018A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023285986A1 (en) | 2023-01-19 |
| EP4370538A1 (en) | 2024-05-22 |
| CA3225080A1 (en) | 2023-01-19 |
| CN118019757A (zh) | 2024-05-10 |
| JP2024525742A (ja) | 2024-07-12 |
| IL310018A (en) | 2024-03-01 |
| US20240307559A1 (en) | 2024-09-19 |
| KR20240052746A (ko) | 2024-04-23 |
| AU2022311329A1 (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hsu et al. | CRISPR technologies for stem cell engineering and regenerative medicine | |
| Najafi et al. | Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections | |
| MY209860A (en) | Gene therapy vectors for treating heart disease | |
| WO2021163357A3 (en) | Gene therapy vectors for treating heart disease | |
| FI3795181T3 (fi) | Amd:n hoito aav2-variantilla ja afliberseptillä | |
| CY1119295T1 (el) | Γονιδιακη θεραπεια για ασθενειες λυσοσωμικης αποθhκευσης | |
| EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| PH12020500239A1 (en) | Factor viii (fviii) gene therapy methods | |
| WO2022195074A3 (en) | Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy | |
| WO2022035903A3 (en) | Gene therapies for lysosomal disorders | |
| WO2020142740A8 (en) | Treatment of sjogren's disease with nuclease fusion proteins | |
| MXPA02007448A (es) | Sistema de suministro y metodo para terapia genetica. | |
| MX2024000748A (es) | Terapia génica de kcnv2. | |
| Deng et al. | Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79 | |
| MX2023000945A (es) | 55cepa c de prevotella histicola como terapia oral para enfermedades inflamatorias. | |
| Chiam et al. | Scedosporium prolificans endogenous endophthalmitis | |
| MX2024000747A (es) | Terapia génica con retgc. | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| RU2013130028A (ru) | Новые производные оксадиазола в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) | |
| Ranzenigo et al. | HIV cure-related research: where we stand and where we go | |
| MX2023007029A (es) | Masitinib para el tratamiento de la enfermedad de alzheimer. | |
| Tae | CRISPR, OMEGA, and Fanzor: Mixed Blessings of Genome Editing Technology | |
| MX2026002137A (es) | Proteina hibrida, secuencia nucleotidica hibrida, molecula de acido nucleico, vector para la expresion de proteina hibrida, uso de la proteina hibrida o secuencia nucleotidica, formulacion, proceso para la produccion de una formulacion y metodo para el tratamiento de lesiones y/o cancer causados por la infeccion por el virus del papiloma humano (hpv) | |
| EA202192739A1 (ru) | Генная терапия лизосомальных нарушений | |
| Dau et al. | CONCURRENT REPROGRAMMING AND GENE EDITING OF HUMAN FIBROBLASTS INTO INDUCED PLURIPOTENT STEM CELLS USING DUAL COLOR SINGLE-CYCLE MEASLES VECTORS |